Chandler Capital

Chandler Capital

Expertise: Technology, Pharmaceutical, Energy, GARP

Chandler Capital is the work of Ian Hartana and Vayun Chugh.

Ian Hartana is a self-taught investor whose work has been featured on Seeking Alpha under the organization AlmaStreet Capital. Being on the student advisory board of the Young Investors Society, he is a long-time advocate for the advancement of financial literacy and has competed on the international level in multiple competitions. In his free time, he enjoys exploring the intersection between behavioral science and economics through writing on the platform Medium and is currently working as an intern at a small venture capital firm.

Vayun Chugh is also a self-taught investor and is both an editor and writer for AlmaStreet Capital. He is the president of his school’s finance club alongside Ian Hartana, and has also competed in multiple international competitions. Through his ongoing research in the medical field, Vayun has developed a deep understanding of the pharmaceutical industry and knows the characteristics of an undervalued company.

Ian and Vayun’s expertise lies in finding value in undervalued companies in the tech, pharmaceutical, and energy sectors which have the potential for growth at a reasonable price. They have a long-term investment horizon and consider ESG as an increasingly important factor in their research process.

Recent Articles

Wall Street Favorites: 3 Fintech Stocks With Strong Buy Ratings for May 2024

As the world sees a shift toward global payment services, financial technology will benefit. Here are three fintech stocks to buy this May!

3 Cryptos That Are Causing a Stir in the Financial World

As blockchain technology only continues to evolve, here are three disruptive cryptocurrencies that are already causing a stir.

Metaverse Moguls: 3 Stocks Poised to Dominate the Virtual Realm

Although Metaverse's billions of dollars in investments have yet to materialize, get a head start with three leading Metaverse stocks to buy.

3 Cheap Biotech Stocks to Buy Now: May 2024

Many of these cheap biotech stocks are on their way to achieving FDA approval for their drugs to enter the market.

Wall Street Favorites: 3 EV Stocks With Strong Buy Ratings for May 2024

While the hype around EV stocks has waned, a market rebound sets these three EV analyst pick stocks a step ahead.